Global Stem Cells research
Global Stem Cells research

Stem Cells Comprehensive Study by Type (Adult Stem Cells (Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others), Human Embryonic Stem Cells (hESC), Induced Pluripotent Stem Cells, Very Small Embryonic-Like Stem Cells), Application (Regenerative Medicine (Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others), Drug Discovery and Development), Technology (Cell Acquisition (Bone Marrow Harvest, Umbilical Blood Cord, Apheresis), Cell Production (Therapeutic Cloning, In-vitro Fertilization, Cell Culture, Isolation), Cryopreservation, Expansion and Sub-Culture), Therapy (Autologous, Allogeneic) Players and Region - Global Market Outlook to 2024

Stem Cells Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jun 2019 Edition 238 Pages 173 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Stem Cells Market Scope
The stem cell is used for treating chronic diseases such as cardiovascular disorders, cancer, diabetes, and others. Growing research and development in stem cell isolation techniques propelling market growth. For instance, a surgeon from Turkey developed a method for obtaining stem cells from the human body without enzymes which are generally used for the isolation of stem cells. Further, growing healthcare infrastructure in the developing economies and government spending on the life science research and development expected to drive the demand for stem cell market over the forecasted period.

The market study is being classified by Type (Adult Stem Cells [Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others], Human Embryonic Stem Cells (hESC), Induced Pluripotent Stem Cells and Very Small Embryonic-Like Stem Cells), by Application (Regenerative Medicine [Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others] and Drug Discovery and Development) and major geographies with country level break-up.

Leading global players are focusing on strategic partnerships to improve their products and services. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Stem Cells market throughout the predicted period.

Smith & Nephew (United Kingdom), Celgene Corporation (United States), BIOTIME, INC. (United States), Cynata (Australia), Applied Cell Technology (Hungary), STEMCELL Technologies Inc. (Canada), BioTime Inc. (United States), Cytori Therapeutics, Inc. (United States), Astellas Pharma Inc. (Japan), U.S. Stem Cell, Inc. (United States) and Takara Holdings. (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Caladrius Biosciences, Inc. (United States), Cellular Engineering Technologies Inc. (United States) and BrainStorm Cell Therapeutics Inc. (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Stem Cells market by Type, Application and Region.

On the basis of geography, the market of Stem Cells has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology , the sub-segment i.e. Cell Acquisition [Bone Marrow Harvest, Umbilical Blood Cord, Apheresis] will boost the Stem Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy , the sub-segment i.e. Autologous will boost the Stem Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.


“The Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) regulates human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. Stem cells come from different sources and are used in a variety of procedures or applications. Stem cells from bone marrow, umbilical cord blood or peripheral blood are routinely used in transplantation procedures to treat patients with cancer and other disorders of the blood and immune system. Stem cells sourced from cord blood for unrelated allogeneic use also are regulated by the FDA, and a license is required for distribution of these products.”

Market Trend
  • Emphasizing On Development of Regenerative Medicine
  • Technological Advancement in Stem Cell Harvesting and Isolation Techniques

Market Drivers
  • Rising Prevalence of Chronic Diseases such as Cardiovascular Disorders, Cancer, and others
  • Growing Healthcare Infrastructure in the Developing Economies

Opportunities
  • Growing Demand for Cellular Therapies
  • Rising Application of Autologous Therapy

Restraints
  • Stringent Government Regulations Regarding Stem Cells
  • Lack of Skilled Professionals

Challenges
  • Lack of Awareness Regarding Stem Cell Therapy in the Low and Middle Income Group Countries


Key Target Audience
Healthcare Institution, Contract Research Manufacturers, Associations, Organizations, Forums, and Alliances, Government Bodies and Departments, Research Institutes and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Adult Stem Cells [Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others]
  • Human Embryonic Stem Cells (hESC)
  • Induced Pluripotent Stem Cells
  • Very Small Embryonic-Like Stem Cells
By Application
  • Regenerative Medicine [Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others]
  • Drug Discovery and Development
By Technology
  • Cell Acquisition [Bone Marrow Harvest, Umbilical Blood Cord, Apheresis]
  • Cell Production [Therapeutic Cloning, In-vitro Fertilization, Cell Culture, Isolation]
  • Cryopreservation
  • Expansion and Sub-Culture

By Therapy
  • Autologous
  • Allogeneic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases such as Cardiovascular Disorders, Cancer, and others
      • 3.2.2. Growing Healthcare Infrastructure in the Developing Economies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Regarding Stem Cell Therapy in the Low and Middle Income Group Countries
    • 3.4. Market Trends
      • 3.4.1. Emphasizing On Development of Regenerative Medicine
      • 3.4.2. Technological Advancement in Stem Cell Harvesting and Isolation Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Stem Cells, by Type, Application, Technology , Therapy and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Stem Cells (Value)
      • 5.2.1. Global Stem Cells by: Type (Value)
        • 5.2.1.1. Adult Stem Cells [Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others]
        • 5.2.1.2. Human Embryonic Stem Cells (hESC)
        • 5.2.1.3. Induced Pluripotent Stem Cells
        • 5.2.1.4. Very Small Embryonic-Like Stem Cells
      • 5.2.2. Global Stem Cells by: Application (Value)
        • 5.2.2.1. Regenerative Medicine [Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others]
        • 5.2.2.2. Drug Discovery and Development
      • 5.2.3. Global Stem Cells Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Stem Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Smith & Nephew (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celgene Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BIOTIME, INC. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cynata (Australia)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Applied Cell Technology (Hungary)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. STEMCELL Technologies Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioTime Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cytori Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astellas Pharma Inc. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. U.S. Stem Cell, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Takara Holdings. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Stem Cells Sale, by Type, Application, Technology , Therapy and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Stem Cells (Value)
      • 7.2.1. Global Stem Cells by: Type (Value)
        • 7.2.1.1. Adult Stem Cells [Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others]
        • 7.2.1.2. Human Embryonic Stem Cells (hESC)
        • 7.2.1.3. Induced Pluripotent Stem Cells
        • 7.2.1.4. Very Small Embryonic-Like Stem Cells
      • 7.2.2. Global Stem Cells by: Application (Value)
        • 7.2.2.1. Regenerative Medicine [Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others]
        • 7.2.2.2. Drug Discovery and Development
      • 7.2.3. Global Stem Cells Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Stem Cells: by Type(USD Million)
  • Table 2. Stem Cells Adult Stem Cells [Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others] , by Region USD Million (2013-2018)
  • Table 3. Stem Cells Human Embryonic Stem Cells (hESC) , by Region USD Million (2013-2018)
  • Table 4. Stem Cells Induced Pluripotent Stem Cells , by Region USD Million (2013-2018)
  • Table 5. Stem Cells Very Small Embryonic-Like Stem Cells , by Region USD Million (2013-2018)
  • Table 6. Stem Cells: by Application(USD Million)
  • Table 7. Stem Cells Regenerative Medicine [Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others] , by Region USD Million (2013-2018)
  • Table 8. Stem Cells Drug Discovery and Development , by Region USD Million (2013-2018)
  • Table 9. South America Stem Cells, by Country USD Million (2013-2018)
  • Table 10. South America Stem Cells, by Type USD Million (2013-2018)
  • Table 11. South America Stem Cells, by Application USD Million (2013-2018)
  • Table 12. South America Stem Cells, by Technology USD Million (2013-2018)
  • Table 13. South America Stem Cells, by Therapy USD Million (2013-2018)
  • Table 14. Brazil Stem Cells, by Type USD Million (2013-2018)
  • Table 15. Brazil Stem Cells, by Application USD Million (2013-2018)
  • Table 16. Brazil Stem Cells, by Technology USD Million (2013-2018)
  • Table 17. Brazil Stem Cells, by Therapy USD Million (2013-2018)
  • Table 18. Argentina Stem Cells, by Type USD Million (2013-2018)
  • Table 19. Argentina Stem Cells, by Application USD Million (2013-2018)
  • Table 20. Argentina Stem Cells, by Technology USD Million (2013-2018)
  • Table 21. Argentina Stem Cells, by Therapy USD Million (2013-2018)
  • Table 22. Rest of South America Stem Cells, by Type USD Million (2013-2018)
  • Table 23. Rest of South America Stem Cells, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Stem Cells, by Technology USD Million (2013-2018)
  • Table 25. Rest of South America Stem Cells, by Therapy USD Million (2013-2018)
  • Table 26. Asia Pacific Stem Cells, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Stem Cells, by Type USD Million (2013-2018)
  • Table 28. Asia Pacific Stem Cells, by Application USD Million (2013-2018)
  • Table 29. Asia Pacific Stem Cells, by Technology USD Million (2013-2018)
  • Table 30. Asia Pacific Stem Cells, by Therapy USD Million (2013-2018)
  • Table 31. China Stem Cells, by Type USD Million (2013-2018)
  • Table 32. China Stem Cells, by Application USD Million (2013-2018)
  • Table 33. China Stem Cells, by Technology USD Million (2013-2018)
  • Table 34. China Stem Cells, by Therapy USD Million (2013-2018)
  • Table 35. Japan Stem Cells, by Type USD Million (2013-2018)
  • Table 36. Japan Stem Cells, by Application USD Million (2013-2018)
  • Table 37. Japan Stem Cells, by Technology USD Million (2013-2018)
  • Table 38. Japan Stem Cells, by Therapy USD Million (2013-2018)
  • Table 39. India Stem Cells, by Type USD Million (2013-2018)
  • Table 40. India Stem Cells, by Application USD Million (2013-2018)
  • Table 41. India Stem Cells, by Technology USD Million (2013-2018)
  • Table 42. India Stem Cells, by Therapy USD Million (2013-2018)
  • Table 43. South Korea Stem Cells, by Type USD Million (2013-2018)
  • Table 44. South Korea Stem Cells, by Application USD Million (2013-2018)
  • Table 45. South Korea Stem Cells, by Technology USD Million (2013-2018)
  • Table 46. South Korea Stem Cells, by Therapy USD Million (2013-2018)
  • Table 47. Taiwan Stem Cells, by Type USD Million (2013-2018)
  • Table 48. Taiwan Stem Cells, by Application USD Million (2013-2018)
  • Table 49. Taiwan Stem Cells, by Technology USD Million (2013-2018)
  • Table 50. Taiwan Stem Cells, by Therapy USD Million (2013-2018)
  • Table 51. Australia Stem Cells, by Type USD Million (2013-2018)
  • Table 52. Australia Stem Cells, by Application USD Million (2013-2018)
  • Table 53. Australia Stem Cells, by Technology USD Million (2013-2018)
  • Table 54. Australia Stem Cells, by Therapy USD Million (2013-2018)
  • Table 55. Rest of Asia-Pacific Stem Cells, by Type USD Million (2013-2018)
  • Table 56. Rest of Asia-Pacific Stem Cells, by Application USD Million (2013-2018)
  • Table 57. Rest of Asia-Pacific Stem Cells, by Technology USD Million (2013-2018)
  • Table 58. Rest of Asia-Pacific Stem Cells, by Therapy USD Million (2013-2018)
  • Table 59. Europe Stem Cells, by Country USD Million (2013-2018)
  • Table 60. Europe Stem Cells, by Type USD Million (2013-2018)
  • Table 61. Europe Stem Cells, by Application USD Million (2013-2018)
  • Table 62. Europe Stem Cells, by Technology USD Million (2013-2018)
  • Table 63. Europe Stem Cells, by Therapy USD Million (2013-2018)
  • Table 64. Germany Stem Cells, by Type USD Million (2013-2018)
  • Table 65. Germany Stem Cells, by Application USD Million (2013-2018)
  • Table 66. Germany Stem Cells, by Technology USD Million (2013-2018)
  • Table 67. Germany Stem Cells, by Therapy USD Million (2013-2018)
  • Table 68. France Stem Cells, by Type USD Million (2013-2018)
  • Table 69. France Stem Cells, by Application USD Million (2013-2018)
  • Table 70. France Stem Cells, by Technology USD Million (2013-2018)
  • Table 71. France Stem Cells, by Therapy USD Million (2013-2018)
  • Table 72. Italy Stem Cells, by Type USD Million (2013-2018)
  • Table 73. Italy Stem Cells, by Application USD Million (2013-2018)
  • Table 74. Italy Stem Cells, by Technology USD Million (2013-2018)
  • Table 75. Italy Stem Cells, by Therapy USD Million (2013-2018)
  • Table 76. United Kingdom Stem Cells, by Type USD Million (2013-2018)
  • Table 77. United Kingdom Stem Cells, by Application USD Million (2013-2018)
  • Table 78. United Kingdom Stem Cells, by Technology USD Million (2013-2018)
  • Table 79. United Kingdom Stem Cells, by Therapy USD Million (2013-2018)
  • Table 80. Netherlands Stem Cells, by Type USD Million (2013-2018)
  • Table 81. Netherlands Stem Cells, by Application USD Million (2013-2018)
  • Table 82. Netherlands Stem Cells, by Technology USD Million (2013-2018)
  • Table 83. Netherlands Stem Cells, by Therapy USD Million (2013-2018)
  • Table 84. Rest of Europe Stem Cells, by Type USD Million (2013-2018)
  • Table 85. Rest of Europe Stem Cells, by Application USD Million (2013-2018)
  • Table 86. Rest of Europe Stem Cells, by Technology USD Million (2013-2018)
  • Table 87. Rest of Europe Stem Cells, by Therapy USD Million (2013-2018)
  • Table 88. MEA Stem Cells, by Country USD Million (2013-2018)
  • Table 89. MEA Stem Cells, by Type USD Million (2013-2018)
  • Table 90. MEA Stem Cells, by Application USD Million (2013-2018)
  • Table 91. MEA Stem Cells, by Technology USD Million (2013-2018)
  • Table 92. MEA Stem Cells, by Therapy USD Million (2013-2018)
  • Table 93. Middle East Stem Cells, by Type USD Million (2013-2018)
  • Table 94. Middle East Stem Cells, by Application USD Million (2013-2018)
  • Table 95. Middle East Stem Cells, by Technology USD Million (2013-2018)
  • Table 96. Middle East Stem Cells, by Therapy USD Million (2013-2018)
  • Table 97. Africa Stem Cells, by Type USD Million (2013-2018)
  • Table 98. Africa Stem Cells, by Application USD Million (2013-2018)
  • Table 99. Africa Stem Cells, by Technology USD Million (2013-2018)
  • Table 100. Africa Stem Cells, by Therapy USD Million (2013-2018)
  • Table 101. North America Stem Cells, by Country USD Million (2013-2018)
  • Table 102. North America Stem Cells, by Type USD Million (2013-2018)
  • Table 103. North America Stem Cells, by Application USD Million (2013-2018)
  • Table 104. North America Stem Cells, by Technology USD Million (2013-2018)
  • Table 105. North America Stem Cells, by Therapy USD Million (2013-2018)
  • Table 106. United States Stem Cells, by Type USD Million (2013-2018)
  • Table 107. United States Stem Cells, by Application USD Million (2013-2018)
  • Table 108. United States Stem Cells, by Technology USD Million (2013-2018)
  • Table 109. United States Stem Cells, by Therapy USD Million (2013-2018)
  • Table 110. Canada Stem Cells, by Type USD Million (2013-2018)
  • Table 111. Canada Stem Cells, by Application USD Million (2013-2018)
  • Table 112. Canada Stem Cells, by Technology USD Million (2013-2018)
  • Table 113. Canada Stem Cells, by Therapy USD Million (2013-2018)
  • Table 114. Mexico Stem Cells, by Type USD Million (2013-2018)
  • Table 115. Mexico Stem Cells, by Application USD Million (2013-2018)
  • Table 116. Mexico Stem Cells, by Technology USD Million (2013-2018)
  • Table 117. Mexico Stem Cells, by Therapy USD Million (2013-2018)
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Stem Cells: by Type(USD Million)
  • Table 130. Stem Cells Adult Stem Cells [Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others] , by Region USD Million (2019-2024)
  • Table 131. Stem Cells Human Embryonic Stem Cells (hESC) , by Region USD Million (2019-2024)
  • Table 132. Stem Cells Induced Pluripotent Stem Cells , by Region USD Million (2019-2024)
  • Table 133. Stem Cells Very Small Embryonic-Like Stem Cells , by Region USD Million (2019-2024)
  • Table 134. Stem Cells: by Application(USD Million)
  • Table 135. Stem Cells Regenerative Medicine [Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others] , by Region USD Million (2019-2024)
  • Table 136. Stem Cells Drug Discovery and Development , by Region USD Million (2019-2024)
  • Table 137. South America Stem Cells, by Country USD Million (2019-2024)
  • Table 138. South America Stem Cells, by Type USD Million (2019-2024)
  • Table 139. South America Stem Cells, by Application USD Million (2019-2024)
  • Table 140. South America Stem Cells, by Technology USD Million (2019-2024)
  • Table 141. South America Stem Cells, by Therapy USD Million (2019-2024)
  • Table 142. Brazil Stem Cells, by Type USD Million (2019-2024)
  • Table 143. Brazil Stem Cells, by Application USD Million (2019-2024)
  • Table 144. Brazil Stem Cells, by Technology USD Million (2019-2024)
  • Table 145. Brazil Stem Cells, by Therapy USD Million (2019-2024)
  • Table 146. Argentina Stem Cells, by Type USD Million (2019-2024)
  • Table 147. Argentina Stem Cells, by Application USD Million (2019-2024)
  • Table 148. Argentina Stem Cells, by Technology USD Million (2019-2024)
  • Table 149. Argentina Stem Cells, by Therapy USD Million (2019-2024)
  • Table 150. Rest of South America Stem Cells, by Type USD Million (2019-2024)
  • Table 151. Rest of South America Stem Cells, by Application USD Million (2019-2024)
  • Table 152. Rest of South America Stem Cells, by Technology USD Million (2019-2024)
  • Table 153. Rest of South America Stem Cells, by Therapy USD Million (2019-2024)
  • Table 154. Asia Pacific Stem Cells, by Country USD Million (2019-2024)
  • Table 155. Asia Pacific Stem Cells, by Type USD Million (2019-2024)
  • Table 156. Asia Pacific Stem Cells, by Application USD Million (2019-2024)
  • Table 157. Asia Pacific Stem Cells, by Technology USD Million (2019-2024)
  • Table 158. Asia Pacific Stem Cells, by Therapy USD Million (2019-2024)
  • Table 159. China Stem Cells, by Type USD Million (2019-2024)
  • Table 160. China Stem Cells, by Application USD Million (2019-2024)
  • Table 161. China Stem Cells, by Technology USD Million (2019-2024)
  • Table 162. China Stem Cells, by Therapy USD Million (2019-2024)
  • Table 163. Japan Stem Cells, by Type USD Million (2019-2024)
  • Table 164. Japan Stem Cells, by Application USD Million (2019-2024)
  • Table 165. Japan Stem Cells, by Technology USD Million (2019-2024)
  • Table 166. Japan Stem Cells, by Therapy USD Million (2019-2024)
  • Table 167. India Stem Cells, by Type USD Million (2019-2024)
  • Table 168. India Stem Cells, by Application USD Million (2019-2024)
  • Table 169. India Stem Cells, by Technology USD Million (2019-2024)
  • Table 170. India Stem Cells, by Therapy USD Million (2019-2024)
  • Table 171. South Korea Stem Cells, by Type USD Million (2019-2024)
  • Table 172. South Korea Stem Cells, by Application USD Million (2019-2024)
  • Table 173. South Korea Stem Cells, by Technology USD Million (2019-2024)
  • Table 174. South Korea Stem Cells, by Therapy USD Million (2019-2024)
  • Table 175. Taiwan Stem Cells, by Type USD Million (2019-2024)
  • Table 176. Taiwan Stem Cells, by Application USD Million (2019-2024)
  • Table 177. Taiwan Stem Cells, by Technology USD Million (2019-2024)
  • Table 178. Taiwan Stem Cells, by Therapy USD Million (2019-2024)
  • Table 179. Australia Stem Cells, by Type USD Million (2019-2024)
  • Table 180. Australia Stem Cells, by Application USD Million (2019-2024)
  • Table 181. Australia Stem Cells, by Technology USD Million (2019-2024)
  • Table 182. Australia Stem Cells, by Therapy USD Million (2019-2024)
  • Table 183. Rest of Asia-Pacific Stem Cells, by Type USD Million (2019-2024)
  • Table 184. Rest of Asia-Pacific Stem Cells, by Application USD Million (2019-2024)
  • Table 185. Rest of Asia-Pacific Stem Cells, by Technology USD Million (2019-2024)
  • Table 186. Rest of Asia-Pacific Stem Cells, by Therapy USD Million (2019-2024)
  • Table 187. Europe Stem Cells, by Country USD Million (2019-2024)
  • Table 188. Europe Stem Cells, by Type USD Million (2019-2024)
  • Table 189. Europe Stem Cells, by Application USD Million (2019-2024)
  • Table 190. Europe Stem Cells, by Technology USD Million (2019-2024)
  • Table 191. Europe Stem Cells, by Therapy USD Million (2019-2024)
  • Table 192. Germany Stem Cells, by Type USD Million (2019-2024)
  • Table 193. Germany Stem Cells, by Application USD Million (2019-2024)
  • Table 194. Germany Stem Cells, by Technology USD Million (2019-2024)
  • Table 195. Germany Stem Cells, by Therapy USD Million (2019-2024)
  • Table 196. France Stem Cells, by Type USD Million (2019-2024)
  • Table 197. France Stem Cells, by Application USD Million (2019-2024)
  • Table 198. France Stem Cells, by Technology USD Million (2019-2024)
  • Table 199. France Stem Cells, by Therapy USD Million (2019-2024)
  • Table 200. Italy Stem Cells, by Type USD Million (2019-2024)
  • Table 201. Italy Stem Cells, by Application USD Million (2019-2024)
  • Table 202. Italy Stem Cells, by Technology USD Million (2019-2024)
  • Table 203. Italy Stem Cells, by Therapy USD Million (2019-2024)
  • Table 204. United Kingdom Stem Cells, by Type USD Million (2019-2024)
  • Table 205. United Kingdom Stem Cells, by Application USD Million (2019-2024)
  • Table 206. United Kingdom Stem Cells, by Technology USD Million (2019-2024)
  • Table 207. United Kingdom Stem Cells, by Therapy USD Million (2019-2024)
  • Table 208. Netherlands Stem Cells, by Type USD Million (2019-2024)
  • Table 209. Netherlands Stem Cells, by Application USD Million (2019-2024)
  • Table 210. Netherlands Stem Cells, by Technology USD Million (2019-2024)
  • Table 211. Netherlands Stem Cells, by Therapy USD Million (2019-2024)
  • Table 212. Rest of Europe Stem Cells, by Type USD Million (2019-2024)
  • Table 213. Rest of Europe Stem Cells, by Application USD Million (2019-2024)
  • Table 214. Rest of Europe Stem Cells, by Technology USD Million (2019-2024)
  • Table 215. Rest of Europe Stem Cells, by Therapy USD Million (2019-2024)
  • Table 216. MEA Stem Cells, by Country USD Million (2019-2024)
  • Table 217. MEA Stem Cells, by Type USD Million (2019-2024)
  • Table 218. MEA Stem Cells, by Application USD Million (2019-2024)
  • Table 219. MEA Stem Cells, by Technology USD Million (2019-2024)
  • Table 220. MEA Stem Cells, by Therapy USD Million (2019-2024)
  • Table 221. Middle East Stem Cells, by Type USD Million (2019-2024)
  • Table 222. Middle East Stem Cells, by Application USD Million (2019-2024)
  • Table 223. Middle East Stem Cells, by Technology USD Million (2019-2024)
  • Table 224. Middle East Stem Cells, by Therapy USD Million (2019-2024)
  • Table 225. Africa Stem Cells, by Type USD Million (2019-2024)
  • Table 226. Africa Stem Cells, by Application USD Million (2019-2024)
  • Table 227. Africa Stem Cells, by Technology USD Million (2019-2024)
  • Table 228. Africa Stem Cells, by Therapy USD Million (2019-2024)
  • Table 229. North America Stem Cells, by Country USD Million (2019-2024)
  • Table 230. North America Stem Cells, by Type USD Million (2019-2024)
  • Table 231. North America Stem Cells, by Application USD Million (2019-2024)
  • Table 232. North America Stem Cells, by Technology USD Million (2019-2024)
  • Table 233. North America Stem Cells, by Therapy USD Million (2019-2024)
  • Table 234. United States Stem Cells, by Type USD Million (2019-2024)
  • Table 235. United States Stem Cells, by Application USD Million (2019-2024)
  • Table 236. United States Stem Cells, by Technology USD Million (2019-2024)
  • Table 237. United States Stem Cells, by Therapy USD Million (2019-2024)
  • Table 238. Canada Stem Cells, by Type USD Million (2019-2024)
  • Table 239. Canada Stem Cells, by Application USD Million (2019-2024)
  • Table 240. Canada Stem Cells, by Technology USD Million (2019-2024)
  • Table 241. Canada Stem Cells, by Therapy USD Million (2019-2024)
  • Table 242. Mexico Stem Cells, by Type USD Million (2019-2024)
  • Table 243. Mexico Stem Cells, by Application USD Million (2019-2024)
  • Table 244. Mexico Stem Cells, by Technology USD Million (2019-2024)
  • Table 245. Mexico Stem Cells, by Therapy USD Million (2019-2024)
  • Table 246. Research Programs/Design for This Report
  • Table 247. Key Data Information from Secondary Sources
  • Table 248. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Stem Cells: by Type USD Million (2013-2018)
  • Figure 5. Global Stem Cells: by Application USD Million (2013-2018)
  • Figure 6. South America Stem Cells Share (%), by Country
  • Figure 7. Asia Pacific Stem Cells Share (%), by Country
  • Figure 8. Europe Stem Cells Share (%), by Country
  • Figure 9. MEA Stem Cells Share (%), by Country
  • Figure 10. North America Stem Cells Share (%), by Country
  • Figure 11. Global Stem Cells share by Players 2018 (%)
  • Figure 12. Global Stem Cells share by Players (Top 3) 2018(%)
  • Figure 13. Global Stem Cells share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Smith & Nephew (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Smith & Nephew (United Kingdom) Revenue: by Geography 2018
  • Figure 17. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 18. Celgene Corporation (United States) Revenue: by Geography 2018
  • Figure 19. BIOTIME, INC. (United States) Revenue, Net Income and Gross profit
  • Figure 20. BIOTIME, INC. (United States) Revenue: by Geography 2018
  • Figure 21. Cynata (Australia) Revenue, Net Income and Gross profit
  • Figure 22. Cynata (Australia) Revenue: by Geography 2018
  • Figure 23. Applied Cell Technology (Hungary) Revenue, Net Income and Gross profit
  • Figure 24. Applied Cell Technology (Hungary) Revenue: by Geography 2018
  • Figure 25. STEMCELL Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 26. STEMCELL Technologies Inc. (Canada) Revenue: by Geography 2018
  • Figure 27. BioTime Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. BioTime Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Cytori Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cytori Therapeutics, Inc. (United States) Revenue: by Geography 2018
  • Figure 31. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Astellas Pharma Inc. (Japan) Revenue: by Geography 2018
  • Figure 33. U.S. Stem Cell, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. U.S. Stem Cell, Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Takara Holdings. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Takara Holdings. (Japan) Revenue: by Geography 2018
  • Figure 37. Global Stem Cells: by Type USD Million (2019-2024)
  • Figure 38. Global Stem Cells: by Application USD Million (2019-2024)
  • Figure 39. South America Stem Cells Share (%), by Country
  • Figure 40. Asia Pacific Stem Cells Share (%), by Country
  • Figure 41. Europe Stem Cells Share (%), by Country
  • Figure 42. MEA Stem Cells Share (%), by Country
  • Figure 43. North America Stem Cells Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Smith & Nephew (United Kingdom)
  • Celgene Corporation (United States)
  • BIOTIME, INC. (United States)
  • Cynata (Australia)
  • Applied Cell Technology (Hungary)
  • STEMCELL Technologies Inc. (Canada)
  • BioTime Inc. (United States)
  • Cytori Therapeutics, Inc. (United States)
  • Astellas Pharma Inc. (Japan)
  • U.S. Stem Cell, Inc. (United States)
  • Takara Holdings. (Japan)
Additional players considered in the study are as follows:
Caladrius Biosciences, Inc. (United States) , Cellular Engineering Technologies Inc. (United States) , BrainStorm Cell Therapeutics Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation